Aathavan Shanmuga Anandan

Aathavan Shanmuga Anandan

Auto-generated profile, based on publicly available information

Aathavan Shanmuga Anandan

Mater Hospital Brisbane South Brisbane Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Addiction
Verified
Journal Article
Open access
TSTianze Sun
Tianze Sun
AAAathavan Anandan
Aathavan Anandan
CLCarmen Lim
Carmen Lim
KEKatherine East
Katherine East
SXshaowei xu
shaowei xu
GCGary C. K. Chan
Gary C. K. Chan
Background and Aims: Heated tobacco products (HTPs) are electronic devices that heat process tobacco to release an aerosol containing nicotine and other chemicals. Limited data exist on world‐wide HTP use prevalence. This meta‐analytic review estimated the prevalence of HTP use by country, World Health Organization (WHO) region, year, sex/gender and age.Methods: Five databases (Web of Science, Scopus, Embase, PubMed and PsycINFO) were searched between January 2015 and May 2022. Included studies reported the prevalence of HTP use in nationally representative samples post‐modern HTP device market entry (2015). A random‐effects meta‐analysis was used to estimate overall prevalence for life‐time, current and daily HTP use.Results: Forty‐five studies (n = 1 096 076) from 42 countries/areas from the European Region (EUR), Western Pacific Region (WPR), Region of the Americas (AMR) and African Region (AFR) met inclusion criteria. Estimated pooled prevalence for life‐time, current and daily HTP use was 4.87% [95% confidence interval (CI) = 4.16, 5.63], 1.53% (95% CI = 1.22, 1.87) and 0.79% (95% CI = 0.48, 1.18), respectively, across all years (2015–22). Life‐time HTP use prevalence significantly increased by 3.39% for WPR [0.52% (95% CI = 0.25, 0.88) in 2015 to 3.91% (95% CI = 2.30, 5.92) in 2019] and 5.58% for EUR [1.13% (95% CI = 0.59, 1.97) in 2016 to 6.98% (95% CI = 5.69, 8.39) in 2020]. Current HTP use increased by 10.45% for WPR [0.12% (95% CI = 0, 0.37) in 2015 to 10.57% (95% CI = 5.59, 16.88) in 2020] and 1.15% for EUR [0% (95% CI = 0, 0.35) in 2016 to 1.15% (95% CI = 0.87, 1.47) in 2020]. Meta‐regression revealed higher current HTP use in WPR [3.80% (95% CI = 2.88, 4.98)] compared with EUR [1.40% (95% CI = 1.09, 1.74)] and AMR [0.81% (95% CI = 0.46, 1.26)] and for males [3.45% (95% CI = 2.56, 4.47)] compared with females [1.82% (95% CI = 1.39, 2.29)]. Adolescents had higher life‐time HTP use prevalence [5.25% (95% CI = 4.36, 6.21) than adults [2.45% (95% CI = 0.79, 4.97)]. Most studies scored a low risk of sampling bias due to their nationally representative sampling.Conclusion: The prevalence of HTPs use increased in the EUR and WPR between 2015 and 2020, with nearly 5% of the included populations having ever tried HTP and 1.5% identifying as current users during the study period.

2 May 2023 in Drug and Alcohol Review
Verified
Journal Article
Open access
AAAathavan Shanmuga Anandan
Aathavan Shanmuga Anandan
Janni LeungJanni Leung
Janni Leung
GCGary C. K. Chan
Gary C. K. Chan
TSTianze Sun
Tianze Sun
JCJason P. Connor
Jason P. Connor
DSDaniel Stjepanovic
Daniel Stjepanovic
Issues: Established literature suggests that electronic cigarettes (EC) are more effective than traditional nicotine replacement therapies (NRT) as a smoking cessation aid, but the factors that mediate this difference remain poorly understood. We examine how adverse events (AE) associated with EC use relative to NRTs differ, with the view that differences in AEs experienced may drive differences in use and compliance.Approach: Papers for inclusion were identified via a three‐tiered search strategy. Eligible articles involved healthy participants and compared nicotine ECs to non‐nicotine ECs or NRTs and reported frequency of AE as an outcome. Random‐effects meta‐analyses were conducted to compare the likelihood for each of the AEs between nicotine ECs, non‐nicotine placebo ECs and NRTs.Key Findings: A total of 3756 papers were identified, of which 18 were meta‐analysed (10 cross‐sectional and 8 randomised controlled trials). Meta‐analytic results found no significant difference in the rates of reported AEs (i.e., cough, oral irritation, nausea) between nicotine ECs and NRTs, and between nicotine and non‐nicotine placebo ECs.Implications: The variation in the incidence of AEs likely does not explain user preferences of ECs to NRTs. Incidence of common AEs reported because of EC and NRT use did not differ significantly. Future work will need to quantify both the adverse and favourable effects of ECs to understand the experiential mechanisms that drive the high uptake of nicotine ECs relative to established NRTs.Conclusions: There is inconclusive evidence on the incidence of AEs experience when using ECs compared to NRTs, possibly given the small sample size of studies.

20 July 2022 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AAAathavan Shanmuga Anandan
Aathavan Shanmuga Anandan
MSMunasinghe Silva
Munasinghe Silva
With rising rates of atherosclerotic disease and obesity worldwide, the prevalence of chronic mesenteric ischemia (CMI) has been progressively rising. Prompt diagnosis and early intervention are crucial to avoid bowel loss and mortality in optimising long-term outcomes for patients and achieving symptom relief. This article aims to summarise relevant literature on CMI, enabling primary care physicians to make a timely diagnosis and intervention, improving outcomes of patients with CMI. CMI is often mistaken for more common pathologies due to its non-specific history and physical examination findings. A missed diagnosis can end up in acute mesenteric infarction and bowel perforation which can cause severe morbidity and mortality. Thus, a thorough gastrointestinal disease work-up ruling out other conditions may be required. CT angiogram is the gold standard non-invasive investigation for confirming a CMI diagnosis. Referral to vascular surgery with early surgical intervention through angioplasty and stenting is crucial for improving patient outcomes. Long-term follow-up of patients through routine consultations and serial non-invasive imaging can monitor for recurrence and disease progression.

9 April 2025 in Crohn's & Colitis 360
Verified
Journal Article
Open access
RGRobert Gilmore
Robert Gilmore
RFRichard Fernandes
Richard Fernandes
TSTamar Schildkraut
Tamar Schildkraut
RJRiddhi Joshi
Riddhi Joshi
LLLyman Lin
Lyman Lin
EWEmily K Wright
Emily K Wright
Background: Antitumor necrosis factor (TNF) dose escalation is performed to improve therapeutic response and optimize outcomes in patients with Crohn’s disease (CD). We aimed to describe the durability of anti-TNF therapy in patients with CD receiving escalated anti-TNF therapy, along with the overall durability of anti-TNF treatment between patients managed with a proactive versus reactive therapeutic drug monitoring (TDM) approach. Methods: We undertook a retrospective multicentre cohort study. One center practiced proactive TDM with a weekly virtual TDM clinic, while the other practiced reactive TDM. Patients receiving escalated infliximab or adalimumab therapy for CD from January 2015 to April 2022 were included. Durability was defined as the time from biologic start to cessation for treatment failure. Results: 239 patients (45% female, median age 39) meeting criteria for inclusion were identified; 165 patients were included in the proactive TDM cohort and 74 in the reactive TDM cohort. Anti-TNF naïve patients had significantly higher durability of therapy when compared with the anti-TNF exposed patients for both overall durability (P = .045) and durability postescalation (P = .017). The proactive TDM cohort had significantly higher durability when compared with the reactive cohort for both overall durability (P = .001) and durability postescalation (P = .002). Conclusions: This multicentre, retrospective cohort study illustrates the importance of dose escalation as a therapeutic strategy in IBD care. The durability of anti-TNF therapy is superior in anti-TNF naïve compared to exposed patients and can be improved further by proactive TDM to guide dose optimization.

9 September 2022 in Journal of Patient Safety and Risk Management
Verified
Journal Article
Closed access
AAAathavan Shanmuga Anandan
Aathavan Shanmuga Anandan
DJDavid Johnson
David Johnson
Objectives: Identifying and recording system failures through incident reporting and enacting appropriate preventative change improves patient outcomes. This study identified the characteristics of a hospital incident report, based on severity of incident (Safety Assessment Code (SAC)) score, classification of report and reporter occupation, that prompted reviewer feedback and stimulated organisational change. Methods: Incident reports registered within the RiskMan data repository between January to December 2020 were collated. During the 12-month period, a total of 2250 reports were recorded within the data repository. Feedback was provided for 71 of these reports, with 19 of these reports constituting organisational change. Results: Four key findings were determined by the study. Deterioration was the most likely classification of the incident report to receive feedback, as well as feedback of organisational change. SAC 1 reports were significantly more likely to receive feedback than SAC 3 & 4. There was no significant difference in receiving organisational change feedback between SAC 1 and SAC 2. Incident reports by ‘medical’ staff were significantly more likely to receive feedback than ‘nursing’, ‘admin’, and ‘other’ occupations. Conclusions: This study identified characteristics of incident reporting that result in organisational change recommendations. The small number of incident reports that received feedback is an area for improvement in this clinical site. Understanding the nature of the incident reports that are prioritised when making organisational change can shed light on further areas for improvement. Future investigations could examine which recommendations were implemented, as well as evaluate the barriers and enablers to executing change.

14 November 2022
Verified
Open access
MSMunasinghe Silva
Munasinghe Silva
AAAathavan Shanmuga Anandan
Aathavan Shanmuga Anandan
This case outlines a 71-year-old male falling from body height horizontally across a log with isolated superior mesenteric artery vascular injury, a rarity in minor blunt force trauma. A computed tomography abdomen and pelvis with contrast was ordered revealing active contrast blush arising from a major mesenteric vessel consistent with active arterial bleeding. Bowels and solid intra-abdominal organs were spared from any injuries. He underwent an emergency laparotomy following immediate resuscitation. The bleeding was controlled with clamping of the proximal and distal segments of the superior mesenteric artery (SMA). A severed branch of SMA was identified and ligated to stop the haemorrhage. The patient's recovery was uncomplicated, and he was discharged home on post-operative day 8. This case report highlights a unique mechanism of injury causing a rare injury pattern, emphasizing the importance of early recognition and definitive surgical intervention.